

Neurotech

31 March 2021

Human Clinical Trial Update

Highlights:

- **World first trial assessing full spectrum medicinal cannabis plant with less than 0.3% THC for children (aged 5 to 17) with Autism Spectrum Disorder.**
- **Electronic data collection systems will be used throughout the study to capture real time data.**
- **Trial set to commence shortly with the issuing of the formal approval (including Trial Registration Number).**
- **Results will drive research and trials into various other neurological disorders including potentially Multiple Sclerosis, Epilepsy and Parkinson's Disease.**

Neurotech International Limited (ASX: NTI) ("Neurotech" "NTI" or "the Company") is pleased to provide the following update with respect to its upcoming Phase I/II open label study to evaluate the safety and efficacy of orally administered NTI/DOLCE full spectrum medicinal cannabis plant extract in children with Autism Spectrum Disorder ("ASD").

Preparations are almost complete for NTI to commence its first human clinical trial focussed on paediatric patients suffering from ASD. The trial will be a Phase I/II open label study to evaluate the safety and efficacy of orally administered NTI/DOLCE full spectrum medicinal cannabis plant extract. Importantly, this will be a world first trial assessing full spectrum (multiple cannabinoid) plant with less than 0.3% THC for children (aged 5 to 17) with ASD.

The Company has completed a number of key steps, including:

- Completing trial design and protocols.
- Development of a final formulation for treatment delivery to patients.
- Development of a number of electronic data collection systems that will be used throughout the study to capture real time data including electronic psychologist assessments and electronic auditing and patient compliance systems to ensure patient compliance is achieved and patient feedback is continuously received.

Commenting on the upcoming commencement of the clinical study, Brian Leedman, Chairman of Neurotech International said, "It is exciting to be able to conduct these first in-human studies at Monash Children's Hospital to assess the safety and efficacy of our cannabis strains in children with ASD. The trial participant recruitment was extremely encouraging and with trial commencement imminent, the Company believes that positive results will pave the way for larger studies to address the unmet need for effective treatments in a number of broader neurological conditions".

Authority

This announcement has been authorised for release by the Board of the Company.

Neurotech International Ltd

ABN 73 610 205 402

Suite 5 CPC, 145 Stirling Highway

Nedlands, Western Australia 6009

www.neurotechinternational.com

Further Information

Brian Leedman
Chairman
bleedman@neurotechinternational.com
+61 (0)41 228 1780

Winton Willesee
Non-Executive Director
winton@azc.com.au
+61 (0)41 066 7844

About Neurotech

Neurotech International Limited is a medical device and solutions company conducting clinical studies to assess the neuro-protective, anti-inflammatory and neuro-modulatory activities of our proprietary NTI/Dolce cannabis strains. Neurotech is also commercialising Mente, the world's first home therapy that is clinically proven to increase engagement and improve relaxation in autistic children with elevated Delta band brain activity. For more information about Neurotech please visit <http://www.neurotechinternational.com>

Neurotech International Ltd

ABN 73 610 205 402
Suite 5 CPC, 145 Stirling Highway
Nedlands, Western Australia 6009
www.neurotechinternational.com